PTO Keeps Patent Claim Standard Broad; Spotlight Shifts To Supreme Court
This article was originally published in The Pink Sheet Daily
Executive Summary
Brand pharma gets a few wins in final rule on Patent Trial and Appeal Board practices, but not the big shift it was seeking.
You may also be interested in...
Patent Owners Would Get Better Shot At Quashing IPR Petitions Under USPTO Rule
Proposed rule would eliminate petitioner advantage when patent board is deciding whether to institute inter partes review of patent claims.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.